Online Inquiry
Ixazomib Citrate (MLN9708)
SPC-01132
CAS No. 1201902-80-8
| Size | Price |
| 10 mM (1 mL in DMSO) | Online Inquiry |
| 5 mg | Online Inquiry |
| 10 mg | Online Inquiry |
| 50 mg | Online Inquiry |
| Bulk Size | Online Inquiry |
Proteasome inhibitor ; Autophagy activator
| Description |
|---|
| Ixazomib Citrate (MLN9708) immediately hydrolyzed to Ixazomib (MLN2238), the biologically active form, on exposure to aqueous solutions or plasma. Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Ixazomib (MLN2238) induces autophagy. Phase 3. |
| Product Details | |
|---|---|
| CAS No. | CAS No. 1201902-80-8 |
| Description | Ixazomib Citrate (MLN9708) immediately hydrolyzed to Ixazomib (MLN2238), the biologically active form, on exposure to aqueous solutions or plasma. Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Ixazomib (MLN2238) induces autophagy. Phase 3. |
| Formula | C20H23BCl2N2O9 |
| Molecular Weight | 517.12 |
| Storage | 3 years -20°C powder 2 years -80°C in solvent |
| Synonyms | N/A |
| SMILES | B1(OC(=O)CC(O1)(CC(=O)O)C(=O)O)C(CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl |
| Solubility | DMSO |
| Usage | |
|---|---|
| Storage | 3 years -20°C powder 2 years -80°C in solvent |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.